Older adults who face the highest rates of flu hospitalization moved one step closer to a new vaccine option on June 18, 2026 ...

A Food and Drug Administration advisory panel on Thursday recommended the approval of Moderna’s mRNA-based flu shot for older adults.

By Christy Santhosh and Mariam Sunny June 18 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday backed approval of Moderna's flu vaccine for adults aged 50 and older, saying its ...

VRBPAC endorsed mRNA-1010 for adults 50-64 and ≥65 years, unanimously concluding benefits outweighed risks, supporting a late-stage regulatory path toward potential first mRNA seasonal influenza ...

All nine members of the committee unanimously voted to recommend Moderna's new mRNA influenza vaccine for adults 50 and over.

Older adults who received the high-dose vaccine experienced an 11.5% reduction in hospitalizations related to pneumonia or influenza, a 7.5% reduction in hospitalizations linked to heart and lung ...

The U.S. Food and Drug Administration's advisory panel is set to vote on whether the benefits of Moderna's flu vaccine outweigh its risks in older ‌adults, after regulators reversed course on ...

Moderna's mRNA flu vaccine could be approved by August, but federal policy and a nonfunctional advisory committee threaten ...

National Poll on Healthy Aging data from adults age 50 and over who replied to a poll in late December 2025 and early January 2026 saying that they had not received a flu vaccination in the last six ...

A large Danish trial analysis suggests high-dose flu vaccines may offer extra protection against serious influenza-related hospitalizations in seniors. Study: High-Dose vs Standard-Dose Influenza ...

After receiving the flu vaccine, people sometimes experience achy muscles, fever, headaches, and pain at the injection site.